Solid Biosciences (SLDB) Common Equity (2017 - 2026)

Solid Biosciences has disclosed Common Equity across 10 years of filings, most recently posting $374.1 million for Q1 2026.

• Common Equity for Q1 2026 came in at $374.1 million, up 27.06% year-over-year; the trailing twelve-month figure through Mar 2026 was $374.1 million (up 27.06% YoY), and the FY2025 annual result was $180.0 million, up 31.16% from the prior year.
• Common Equity came in at $374.1 million for Q1 2026 at Solid Biosciences, up from $180.0 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $374.1 million in Q1 2026 to a low of $126.5 million in Q4 2023.
• The 5-year median for Common Equity is $183.8 million (2023), against an average of $197.3 million.
• Across the five-year window, Common Equity tumbled 40.25% in 2023 and surged 39.74% in 2025, its largest moves.
• Solid Biosciences' Common Equity stood at $211.7 million in 2022, then sank by 40.25% to $126.5 million in 2023, then advanced by 8.51% to $137.2 million in 2024, then surged by 31.16% to $180.0 million in 2025, then surged by 107.84% to $374.1 million in 2026.
• The last three Common Equity figures came in at $374.1 million (Q1 2026), $180.0 million (Q4 2025), and $217.9 million (Q3 2025), per Business Quant data.